Hepatitis B virus (HBV) viremia despite tenofovir disoproxil fumarate-containing antiretroviral therapy in persons with HBV/HIV coinfection
Authors:
Open Access
- 2 October 2024
- journal article
- research article
- Published by Elsevier in Journal of Clinical Virology
- Vol. 175, 105733
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 47 references indexed in Scilit:
- Characterization of the tenofovir resistance-associated mutations in the hepatitis B virus isolates across genotypes A to DAntiviral Research, 2022
- Risk of HCC With Hepatitis B Viremia Among HIV/HBV‐Coinfected Persons in North AmericaHepatology, 2021
- Evidence of tenofovir resistance in chronic hepatitis B virus (HBV) infection: An observational case series of South African adultsJournal of Clinical Virology, 2020
- Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacyAntiviral Research, 2018
- HBV‐DNA levels predict overall mortality in HIV/HBV coinfected individualsJournal of Medical Virology, 2015
- Mutations associated with occult hepatitis B in HIV‐positive South AfricansJournal of Medical Virology, 2014
- Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: Virological and clinical implicationsHepatology, 2014
- No Resistance to Tenofovir Disoproxil Fumarate Detected After up to 144 Weeks of Therapy in Patients Monoinfected With Chronic Hepatitis B Virus ΔHepatology, 2010
- Hepatitis B and human immunodeficiency virus coinfection #Hepatology, 2009
- A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand†Hepatology, 2008